Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
pgwGq07etcA7zwwZ
